Pfizer has issued an RFP for Inflammatory and Immune-Mediated Dermatologic Disorders research.
Through the RFP, grants of up to $175,000 will be awarded in support of preclinical, clinical, and outcomes research with the intent to increase medical knowledge in the diagnosis and management of inflammatory and immune-mediated dermatologic disorders. Areas of research focus include mechanistic insights into the role of the JAK/STAT pathway in inflammatory dermatologic diseases; pharmacogenomic studies in atopic dermatitis to identify potential responders to JAK inhibition, including skin color; unmet need and burden of disease of alopecia areata and vitiligo; epidemiological studies in alopecia areata; validation of AD disease severity measures in skin of color; identification of inflammatory pathways related to the pathophysiology of alopecia areata and vitiligo; and identification of immunophenotypic differences in clinical course and treatment response of AD in skin of color.
To be eligible, applicants must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in pharmacy, physiotherapy, or social work. The institution and principal investigator (PI) must be based in the U.S.
See the Pfizer website for complete program guidelines and application instructions.